CTAF Meeting: Migraine

The California Technology Assesment Forum (CTAF), a core program of the Institute for Clinical and Economic Review (ICER), will hold a public meeting on June 14, 2018 to consider the comparative clinical effectiveness and value of CGRP inhibitors for migraine. Migraine is a common, recurrent headache disorder that affects approximately 18% of women and 6% of men in the United States (US). Migraine is among the top ten causes of years lived with disability in the US. When a person experiences a migraine, she or he may feel moderate-to-severe pain and other symptoms (e.g., nausea, vomiting, or sensitivity to light or to sound), have a reduced ability to function, or require bed rest. Despite its high prevalence and impairment, migraine is often not recognized or effectively treated.  ICER will be evaluating the following CGRP inhibitors: Erenumab (Amgen/Novartis), Fremanezumab (Teva), and Galcanezumab (Eli Lilly) for the treatment of migraines.  A list of key dates for stakeholder engagement opportunities and other important information associated with the review of CGRP inhibitors for MIGRAINE PREVENTION CAN BE FOUND ON ICER'S WEBSITE AT https://icer-review.org/topic/migraines/ [https://icer-review.org/topic/migraines/].